Acetylation polymorphism in Khmer population: Clinical consequences;Polymorphisme d'acétylation dans une population khmère: Conséquences cliniques

Therapie

Volumn , Issue 4, 2001, Pages 409-413

  Bechtel, Y C ^a   Bechtel, P R ^a   Lelouet H ^a   Choisy, H ^b   Dy, N R ^c  

^a UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^b Pharmacologie   (France)

^c Secrétariat d'Etal À la Santé   (Cambodia)

Author keywords

Acetylation polymorphism; Inter ethnic variations; Khmers

Indexed keywords

1 METHYLURIC ACID; 1 METHYLXANTHINE; ACYLTRANSFERASE; CAFFEINE; CAFFEINE DERIVATIVE; ISONIAZID; XANTHINE OXIDASE; 1-METHYLURIC ACID; 1-METHYLXANTHINE; 5 ACETAMIDO 6 FORMYLAMINO 3 METHYLURACIL; 5-ACETYLAMINO-6-FORMYLAMINO-3-METHYLURACIL; ARYLAMINE ACETYLTRANSFERASE; CARCINOGEN; DRUG DERIVATIVE; HETEROCYCLIC COMPOUND; TUBERCULOSTATIC AGENT; URACIL; URIC ACID; XANTHINE DERIVATIVE;

ACETYLATOR PHENOTYPE; ARTICLE; CAMBODIA; CAUCASIAN; CONTROLLED STUDY; DRUG ACETYLATION; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PRIORITY JOURNAL; RACE DIFFERENCE; TUBERCULOSIS; URINARY EXCRETION; ACETYLATION; ALLELE; AMINO ACID SUBSTITUTION; ASIAN; BIOTRANSFORMATION; CHROMOSOME 8; COMPARATIVE STUDY; DRUG DETOXIFICATION; DRUG RESISTANCE; ETHNIC GROUP; GENETICS; METABOLISM; NUCLEOTIDE SEQUENCE; PHENOTYPE; URINE;

ACETYLATION; ALLELES; AMINO ACID SUBSTITUTION; ANTITUBERCULAR AGENTS; ARYLAMINE N-ACETYLTRANSFERASE; ASIAN CONTINENTAL ANCESTRY GROUP; BIOTRANSFORMATION; CAFFEINE; CAMBODIA; CARCINOGENS; CHROMOSOMES, HUMAN, PAIR 8; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; HETEROCYCLIC COMPOUNDS; HUMANS; ISONIAZID; METABOLIC DETOXICATION, DRUG; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; TUBERCULOSIS; URACIL; URIC ACID; XANTHINE OXIDASE; XANTHINES;

EID: 0034741203     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Evans DAP, Manley KA. McKusick VA. Genetic control of isoniazid metabolism in man. BMJ 1960; 2: 485-491.
2. Grant DM, Blum M, Meyer UA. Polymorphism of N-acetyltransferase genes. Xenobiotica 1992; 22: 1073-1081.
3. Evans DAP. N-acetyltransferase. Pharmacol Ther 1989; 42: 157-234.
4. Meyer UA. Molecular genetics and the future of pharmacogenetics. Pharmacol Ther 1990; 46: 349-355.
5. Weber WW. The Acetylor Genes and Drug Response. New York: Oxford University Press, 1987.
6. Jenne WW. Partial purification and properties of the isoniazid transacetylase in human liver. Its relationship to the acetylation of p-aminosalicylic acid. J Clin Invest 1965; 44: 1992-2002.
7. Bechtel YC, Bonïti-Pellié C, Poisson N et al. A population and family study of N-acetyltransferase using caffeine urinary metabolites. Clin Pharmacol Ther 1993; 54: 131-141.
8. Weber WW, Hein DW. N-acetylation pharmacogenetics. Pharmacol Rev 1985; 37: 25-79.
9. Grant DM, Tang BK, Kalow W. Variability in caffeine metabolism. Clin Pharmacol Ther 1983; 33: 591-602.
10. Meyer UA. The molecular basis of genetic polymorphisms of drug metabolism. J Pharm Pharmacol 1994; 46: 409-415.
11. Bechtel PR, Bechtel YC. Interethnic differences in arylamine N-acetyltransferase activity. Clinical consequences. In: Pacifici GM, Fracchia GN, eds. Advances in Drug Metabolism in Man. Brussels/Luxembourg: ECSC-EC-EAEC, 1995: 137-147.
12. Neitzel HA. A routine method for the establishment of permanent growing lymphoblastoid. Cell Hum Genet 1986; 73: 320-322.
13. Blum M, Grant DM, McBride W et al. Human arylamine N-acetyltransferase genes: isolation, chromosomal localisation, and functional expression. DNA Cell Biol 1990; 3: 193-203.
14. Ingelman-Sunberg M, Johansson I. The molecular genetic of the human drug metabolizing cytochrome P 450s. In: Pacifici GM, Fracchia GN, eds. Advances in Drug Metabolism in Man. Brussels/Luxembourg: EGSG-EC-EAEC, 1995: 545-585.
15. Grant DM, Morike K, Eichelbaum M, Meyer UA. Acetylation pharmacogenetics. The slow acetylation phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver. J Clin Invest 1990; 85: 968-972.
16. Grant DM, Blum M, Beer M, Meyer UA. Monomorphic and polymorphic human arylamine N-acetyltransferase: a comparison of liver isozymes and expressed products of two cloned genes. Mol Pharmacol 1991; 39: 184-191.
17. Deguchi T. Sequences and expression of alleles of polymorphic arylamine N-acetyltransferase of human liver. J Biol Chem 1992; 267: 18140-18147.
18. Hayes RB, Rothman N. N-acetylation phenotypes and genotypes and risk of bladder cancer in benzidine exposed workers. Carcinogenesis 1993; 14: 675-678.
19. Rothman N, Hayes RB, Bi W et al. Correlation between N-acetyltransferase activity and NAT-2 genotype in Chinese males. Pharmacogenetics 1993; 3: 250-255.